TRIAL RESULTS · SIDE EFFECTS
Daptomycin side effects
ANSWER
14 trials of Daptomycin posted side-effect results, none against placebo, so no placebo rate exists to compare. Most reported: diarrhoea, nausea, rash. Read from ClinicalTrials.gov on 2026-10-03. Not medical advice.
Trial register
Trials with posted results
14
with an arm on Daptomycin, of 132 registered
Against placebo
0
placebo-controlled trials
People in those trials
0
on Daptomycin · 0 on placebo
Read
2026-10-03
ClinicalTrials.gov
ALL TRIALS
The 100 most reported of 400 side effects reported
Every trial with posted results and an arm on Daptomycin (n ≥ 20), all phases, by people affected. Placebo is shown where placebo-controlled trials reported the same event. Comparator arms are not counted.
| Side effect | Organ system | Daptomycin | Placebo | Trials |
|---|---|---|---|---|
| Diarrhoea | Gastrointestinal disorders | 5.2% (38 of 736) | - | 7 |
| Nausea | Gastrointestinal disorders | 4.1% (29 of 702) | - | 6 |
| Rash | Skin and subcutaneous tissue disorders | 5.2% (25 of 479) | - | 6 |
| Blood creatine phosphokinase increased | Investigations | 5.6% (25 of 447) | - | 5 |
| Anaemia | Blood and lymphatic system disorders | 8.9% (24 of 269) | - | 3 |
| Pyrexia | General disorders | 3.3% (20 of 599) | - | 5 |
| Vomiting | Gastrointestinal disorders | 3.0% (18 of 599) | - | 5 |
| Confusion | Nervous system disorders | 47.4% (18 of 38) | - | 1 |
| Increased Creatinine kinase | Metabolism and nutrition disorders | 47.4% (18 of 38) | - | 1 |
| Constipation | Gastrointestinal disorders | 6.8% (15 of 220) | - | 3 |
| Gamma-glutamyltransferase increased | Investigations | 7.6% (15 of 198) | - | 1 |
| Hyperthermia | General disorders | 13.8% (11 of 80) | - | 1 |
| Headache | Nervous system disorders | 1.7% (10 of 599) | - | 5 |
| Hypertension | Vascular disorders | 4.4% (10 of 226) | - | 3 |
| Cough | Respiratory, thoracic and mediastinal disorders | 6.0% (9 of 151) | - | 3 |
| Hypokalaemia | Metabolism and nutrition disorders | 6.2% (9 of 146) | - | 2 |
| ALANINE AMINOTRANSFERASE INCREASED | Investigations | 10.2% (9 of 88) | - | 1 |
| ASPARTATE AMINOTRANSFERASE INCREASED | Investigations | 10.2% (9 of 88) | - | 1 |
| Septic shock | Infections and infestations | 4.0% (8 of 198) | - | 1 |
| Pneumonia | Infections and infestations | 1.4% (7 of 515) | - | 5 |
| Cellulitis | Infections and infestations | 1.7% (7 of 415) | - | 4 |
| Blood pressure increased | Investigations | 4.1% (7 of 169) | - | 3 |
| PYREXIA | General disorders | 6.8% (6 of 88) | - | 1 |
| Pruritus | Skin and subcutaneous tissue disorders | 3.0% (5 of 168) | - | 3 |
| Deep vein thrombosis | Vascular disorders | 2.0% (5 of 247) | - | 2 |
| Blood potassium decreased | Investigations | 2.3% (5 of 220) | - | 2 |
| Insomnia | Psychiatric disorders | 5.2% (5 of 97) | - | 1 |
| Infusion site pain | General disorders | 1.3% (4 of 318) | - | 3 |
| Hyperphosphataemia | Metabolism and nutrition disorders | 1.4% (4 of 278) | - | 2 |
| Staphylococcal bacteraemia | Infections and infestations | 1.8% (4 of 220) | - | 2 |
| Oedema peripheral | General disorders | 8.2% (4 of 49) | - | 1 |
| Urinary tract infection | Infections and infestations | 8.2% (4 of 49) | - | 1 |
| Rhinorrhoea | Respiratory, thoracic and mediastinal disorders | 1.6% (4 of 256) | - | 1 |
| BLOOD POTASSIUM INCREASED | Investigations | 4.5% (4 of 88) | - | 1 |
| C-REACTIVE PROTEIN INCREASED | Investigations | 4.5% (4 of 88) | - | 1 |
| EOSINOPHIL COUNT INCREASED | Investigations | 4.5% (4 of 88) | - | 1 |
| Osteomyelitis | Infections and infestations | 0.4% (3 of 668) | - | 5 |
| Pain in extremity | Musculoskeletal and connective tissue disorders | 1.6% (3 of 185) | - | 4 |
| Chest pain | General disorders | 1.0% (3 of 305) | - | 2 |
| Erythema | Skin and subcutaneous tissue disorders | 4.2% (3 of 71) | - | 2 |
| Hypotension | Vascular disorders | 4.2% (3 of 71) | - | 2 |
| Catheter related complication | General disorders | 6.1% (3 of 49) | - | 1 |
| Bacteriuria | Infections and infestations | 6.1% (3 of 49) | - | 1 |
| Blood alkaline phosphatase increased | Investigations | 6.1% (3 of 49) | - | 1 |
| Anxiety | Psychiatric disorders | 6.1% (3 of 49) | - | 1 |
| Hypertensive crisis | Vascular disorders | 6.1% (3 of 49) | - | 1 |
| Rash papular | Skin and subcutaneous tissue disorders | 1.2% (3 of 256) | - | 1 |
| CONSTIPATION | Gastrointestinal disorders | 3.4% (3 of 88) | - | 1 |
| Cardiac failure | Cardiac disorders | 1.5% (3 of 198) | - | 1 |
| COVID-19 pneumonia | Infections and infestations | 1.5% (3 of 198) | - | 1 |
| Sepsis | Infections and infestations | 0.6% (2 of 321) | - | 3 |
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | 0.7% (2 of 269) | - | 3 |
| Abscess | Infections and infestations | 0.6% (2 of 318) | - | 3 |
| Bacteraemia | Infections and infestations | 0.4% (2 of 476) | - | 3 |
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | 2.2% (2 of 89) | - | 2 |
| Femur fracture | Injury, poisoning and procedural complications | 1.6% (2 of 123) | - | 2 |
| Fungal infection | Infections and infestations | 0.7% (2 of 296) | - | 2 |
| Urticaria | Skin and subcutaneous tissue disorders | 0.7% (2 of 296) | - | 2 |
| Myopathy | Musculoskeletal and connective tissue disorders | 0.4% (2 of 454) | - | 2 |
| Seizure | Nervous system disorders | 0.6% (2 of 316) | - | 2 |
| Haematocrit decreased | Investigations | 4.1% (2 of 49) | - | 1 |
| Haemoglobin decreased | Investigations | 4.1% (2 of 49) | - | 1 |
| Urine output decreased | Investigations | 4.1% (2 of 49) | - | 1 |
| Dizziness | Nervous system disorders | 4.1% (2 of 49) | - | 1 |
| Tremor | Nervous system disorders | 4.1% (2 of 49) | - | 1 |
| Dislocation of joint prosthesis | Injury, poisoning and procedural complications | 4.1% (2 of 49) | - | 1 |
| Rhabdomyolysis | Musculoskeletal and connective tissue disorders | 4.1% (2 of 49) | - | 1 |
| Alanine Aminotransferase Increased | Investigations | 2.1% (2 of 97) | - | 1 |
| Erysipelas | Infections and infestations | 2.1% (2 of 97) | - | 1 |
| Arterial Occlusive Disease | Vascular disorders | 2.1% (2 of 97) | - | 1 |
| Blood phosphorus increased | Investigations | 0.8% (2 of 256) | - | 1 |
| Dermatitis diaper | Skin and subcutaneous tissue disorders | 0.8% (2 of 256) | - | 1 |
| DIARRHOEA | Gastrointestinal disorders | 2.3% (2 of 88) | - | 1 |
| VOMITING | Gastrointestinal disorders | 2.3% (2 of 88) | - | 1 |
| PAIN | General disorders | 2.3% (2 of 88) | - | 1 |
| URINARY TRACT INFECTION | Infections and infestations | 2.3% (2 of 88) | - | 1 |
| BLOOD URINE PRESENT | Investigations | 2.3% (2 of 88) | - | 1 |
| GLUCOSE URINE PRESENT | Investigations | 2.3% (2 of 88) | - | 1 |
| HAEMOGLOBIN DECREASED | Investigations | 2.3% (2 of 88) | - | 1 |
| PLATELET COUNT DECREASED | Investigations | 2.3% (2 of 88) | - | 1 |
| ECZEMA | Skin and subcutaneous tissue disorders | 2.3% (2 of 88) | - | 1 |
| PRURITUS | Skin and subcutaneous tissue disorders | 2.3% (2 of 88) | - | 1 |
| SEPSIS | Infections and infestations | 2.3% (2 of 88) | - | 1 |
| patent foramen ovale | Cardiac disorders | 10.0% (2 of 20) | - | 1 |
| unconjugated hyperbilirubinemia | Blood and lymphatic system disorders | 10.0% (2 of 20) | - | 1 |
| pulmonary edema | Respiratory, thoracic and mediastinal disorders | 10.0% (2 of 20) | - | 1 |
| Pneumatocele | Respiratory, thoracic and mediastinal disorders | 10.0% (2 of 20) | - | 1 |
| Medical device complication | General disorders | 5.0% (2 of 40) | - | 1 |
| Infection | Infections and infestations | 5.0% (2 of 40) | - | 1 |
| Gastrointestinal haemorrhage | Gastrointestinal disorders | 1.0% (2 of 198) | - | 1 |
| Pancreatitis necrotising | Gastrointestinal disorders | 1.0% (2 of 198) | - | 1 |
| Intervertebral discitis | Infections and infestations | 1.0% (2 of 198) | - | 1 |
| Multiple organ dysfunction syndrome | General disorders | 1.0% (2 of 198) | - | 1 |
| Device related infection | Infections and infestations | 0.6% (1 of 163) | - | 3 |
| Viral infection | Infections and infestations | 0.7% (1 of 145) | - | 3 |
| Renal failure acute | Renal and urinary disorders | 0.7% (1 of 142) | - | 3 |
| Arthralgia | Musculoskeletal and connective tissue disorders | 1.4% (1 of 71) | - | 2 |
| Cardiac arrest | Cardiac disorders | 0.4% (1 of 247) | - | 2 |
| Hypersensitivity | Immune system disorders | 1.1% (1 of 89) | - | 2 |
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | 0.8% (1 of 129) | - | 2 |
Source: ClinicalTrials.gov posted results, read 2026-10-03. A trial lists events above its own reporting threshold, so a rare event may be missing from some trials. Not medical advice.
FDA LABEL
What the FDA label says
Daptomycin ANDA216413 · label of 2026-08-26 Regulator
The most common adverse reactions that occurred in ≥2% of adult cSSSI patients receiving daptomycin for injection 4 mg/kg were diarrhea, headache, dizziness, rash, abnormal liver function tests, elevated creatine phosphokinase (CPK), urinary tract infections, hypotension, and dyspnea.
DAPZURA RT NDA213645 · label of 2022-01-25 Regulator
The most common adverse reactions that occurred in ≥2% of adult cSSSI patients receiving daptomycin for injection 4 mg/kg were diarrhea, headache, dizziness, rash, abnormal liver function tests, elevated creatine phosphokinase (CPK), urinary tract infections, hypotension, and dyspnea.
REGISTERED STUDIES
132 registered clinical trials of Daptomycin
The 10 most recently updated are listed.
| NCT00967941 | Vancomycin and Daptomycin Plus Cefazolin for Preoperative Vascular Surgery Prophylaxis Status: COMPLETED · Updated 2026-09-14 |
|---|---|
| NCT06637332 | Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia Status: RECRUITING · Updated 2026-09-09 |
| NCT07376889 | Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia Status: RECRUITING · Updated 2026-08-25 |
| 2024-514952-34-00 | Randomized open-label controlled trial evaluating a single-dose intravenous Dalbavancin versus standard antibiotic therapy during catheterrelated bloodstream infections due to Staphylococcus aureus [DALICATH] Status: UNKNOWN · Updated 2026-07-30 |
| 2023-508442-18-00 | Efficacy and safety of different antimicrobial DURATions for the treatment of Infections associated with Osteosynthesis Material implanted after long bone fractures (DURATIOM). Phase 3 pragmatic multicenter open labelled randomized trial. Status: UNKNOWN · Updated 2026-07-21 |
| 2026-526149-91-00 | Efficacy and safety of Dalbavancin in the treatment of infective Endocarditis caused by gram-positive cocci Status: UNKNOWN · Updated 2026-06-30 |
| NCT07058415 | Impact of Three Probabilistic Antibiotic Therapy on Digestive Microbiota and Colonization With Multi-resistant Bacteria Status: NOT_YET_RECRUITING · Updated 2026-06-22 |
| 2024-519186-21-01 | Efficacy of seven and fourteen days of antibiotic treatment in uncomplicated Staphylococcus aureus bacteremia:
A randomized, non-blinded, non-inferiority interventional study Status: UNKNOWN · Updated 2026-06-18 |
| 2023-503582-35-00 | Staphylococcus aureus Network Adaptive Platform trial (SNAP) Status: UNKNOWN · Updated 2026-05-06 |
| NCT05137119 | Staphylococcus Aureus Network Adaptive Platform Trial Status: RECRUITING · Updated 2026-05-06 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.